Monash researchers discover key to 'superbug' antibiotic resistance
Deaths from antimicrobial resistance could rise to 10 million by 2050, surpassing the total deaths caused by cancer and diabetes combined, according to the World Health Organization. This has prompted the WHO to issue a warning about the need to urgently develop new antibiotics to counter the growing threat of ‘superbugs’.
‘Superbugs’ are bacteria that are resistant to commonly used antibiotics, presenting a global health threat.
To tackle this global challenge, researchers from Monash’s Biomedicine Discovery Institute (BDI) collaborated with Israel’s Weizmann Institute of Science and the NTU Institute of Structural Biology in Singapore. The researchers have now discovered the molecular mechanism by which the potentially deadly superbug ‘Golden Staph’ evades antibiotic treatment, providing the first important clues on how to counter superbug antibiotic resistance. Their findings have been published in the journal mBio.
Researchers used the latest-generation electron microscopes at the Monash Ramaciotti Centre for Electron Microscopy to image at the molecular level — for the first time — the changes that take place in superbugs that have become resistant to the most modern antibiotics.
Examining bacterial samples of antibiotic-resistant Staphylococcus aureus or ‘Golden Staph’ taken from a hospital patient, they compared data of a non-resistant strain with their counterparts overseas. These included Shashi Bhushan from NTU and Zohar Eyal and Nobel Laureate Professor Ada Yonath from the Weizmann Institute who won the Nobel Prize for Chemistry in 2009.
“Using the combined data we could rationalise how the bacteria escapes drug treatment by a really important hospital antibiotic and describe in molecular detail how it becomes like a superbug,” said Monash BDI scientist and lead researcher Dr Matthew Belousoff.
“The bacteria mutates or evolves to change the shape of the molecule to which the antibiotic would bind so the drug can no longer fit there,” Dr Belousoff said.
“Knowing what your enemy is doing is the first step to the next phase of new drug design,” he said.
“We’ve developed a technique that others can use that might help us speed up the arms race of antibiotic development.”
Dr Belousoff said Monash BDI researchers are now using this new tool to investigate other drug-resistant bacteria.
The research, involving the expertise of Monash microscopist Dr Mazdak Radjainia and mentoring of Professor Trevor Lithgow, was supported by the Australian National Health and Medical Research Council (NHMRC).
Monash University scientists have adopted a Single Cell RNA-Seq System, from Dolomite Bio, to...
Regenerative medicine company Avita Medical has announced the execution of an expanded contract...
Paradigm Biopharmaceuticals has received ethics approval for its Phase 2b clinical trial to...